P09.44 Outcomes of Covid-19 Infection in Lung Cancer Patients: Experience from a Large Tertiary Care Cancer Center

Abstract Introduction Among malignant diseases, lung carcinoma is the most common cancer in men worldwide in terms of both incidence and mortality. Its increasing incidence in developing countries like India is an important public health problem. This work aimed to study the demographic, clinical, radiological, and histological features of patients with confirmed lung cancer. Materials and Methods A total of 50 patients with histologically confirmed lung cancer at a tertiary care center in India from August 2016 to September 2018 were studied and analyzed. Results Out of 50 diagnosed lung cancer patients, 86% were men and 14% women; 31 (62%) patients were aged more than 60 years. Majority were smokers (84%) and all were men. Cough (94%) was the most common presenting symptom followed by dyspnea (68%), chest pain (48%), and hemoptysis (38%). Of the 50 patients, 29 (58%) had soft tissue density mass lesion on radiograph. Squamous cell carcinoma (SCC) was the diagnosed histological cell type in 24 (48%) patients and adenocarcinoma in 21 (42%) patients. Distant metastasis was observed in 20 (40%) patients. Conclusion In this study, the most common histopathological cell type is SCC. Patients aged more than 50 years and smokers are at high risk of lung cancer. Patients with a smoking history and persistent respiratory symptoms should be promptly evaluated for lung malignancy.

Download Full-text

Temporal Trends in Demographics and Overall Survival of Non–Small-Cell Lung Cancer Patients at Moffitt Cancer Center from 1986 to 2008

Cancer Control ◽

10.1177/107327481402100107 ◽

2014 ◽

Vol 21 (1) ◽

pp. 51-56 ◽

Cited By ~ 22

Author(s):

Matthew B. Schabath ◽

Zachary J. Thompson ◽

Jhanelle E. Gray

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Temporal Trends ◽

Small Cell ◽

Cancer Center ◽

Small Cell Lung ◽

Lung Cancer Patients

Download Full-text

Epidemiological, clinical profile, and treatment outcome of stage iv nonsquamous nonsmall cell lung cancer patients presenting to tertiary care hospital in North India

Oncology Journal of India ◽

10.4103/oji.oji_34_21 ◽

2021 ◽

Vol 5 (3) ◽

pp. 104

Author(s):

VenkataPradeep Babu Koyyala ◽

Manish Sharma ◽

Pankaj Goyal ◽

Varun Goel ◽

Sravya Bommera ◽

...

Keyword(s):

Lung Cancer ◽

Treatment Outcome ◽

Cancer Patients ◽

Tertiary Care Hospital ◽

Tertiary Care ◽

Stage Iv ◽

Nonsmall Cell Lung Cancer ◽

North India ◽

Care Hospital ◽

Lung Cancer Patients

Download Full-text

Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience.

Journal of Clinical Oncology ◽

10.1200/jco.2020.39.28_suppl.79 ◽

2021 ◽

Vol 39 (28_suppl) ◽

pp. 79-79

Author(s):

Jenny Jing Xiang ◽

Alicia Roy ◽

Christine Summers ◽

Monica Delvy ◽

Jessica Lee O'Donovan ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Trials ◽

Clinical Research ◽

Cancer Patients ◽

Cancer Center ◽

Cancer Type ◽

Eligibility Criteria ◽

Research Recruitment ◽

Lung Cancer Patients ◽

Study Enrollment

79 Background: Patient-trial matching is a critical step in clinical research recruitment that requires extensive review of clinical data and trial requirements. Prescreening, defined as identifying potentially eligible patients using select eligibility criteria, may streamline the process and increase study enrollment. We describe the real-world experience of implementing a standardized, universal clinical research prescreening protocol within a VA cancer center and its impact on research enrollment. Methods: An IRB approved prescreening protocol was implemented at the VACT Cancer Center in March 2017. All patients with a suspected or confirmed diagnosis of cancer are identified through tumor boards, oncology consults, and clinic lists. Research coordinators perform chart review and manually enter patient demographics, cancer type and stage, and treatment history into a REDCap (Research Electronic Data Capture) database. All clinical trials and their eligibility criteria are also entered into REDCap and updated regularly. REDCap generates real time lists of potential research studies for each patient based on his/her recorded data. The primary oncologist is alerted to a patient’s potential eligibility prior to upcoming clinic visits and thus can plan to discuss clinical research enrollment as appropriate. Results: From March 2017 to December 2020, a total of 2548 unique patients were prescreened into REDCAP. The mean age was 71.5 years, 97.5% were male, and 15.5% were African American. 32.57 % patients had genitourinary cancer, 17.15% had lung cancer, and 46.15% were undergoing malignancy workup. 1412 patients were potentially eligible after prescreening and 556 patients were ultimately enrolled in studies. The number of patients enrolled on therapeutic clinical trials increased after the implementation of the prescreening protocol (35 in 2017, 64 in 2018, 78 in 2019, and 55 in 2020 despite the COVID19 pandemic). Biorepository study enrollment increased from 8 in 2019 to 15 in 2020. The prescreening protocol also enabled 200 patients to be enrolled onto a lung nodule liquid biopsy study from 2017 to 2019. Our prescreening process captured 98.57% of lung cancer patients entered into the cancer registry during the same time period. Conclusions: Universal prescreening streamlined research recruitment operations and was associated with yearly increases in clinical research enrollment at a VA cancer center. Our protocol identified most new lung cancer patients, suggesting that, at least for this malignancy, potential study patients were not missed. The protocol was integral in our program becoming the top accruing VA site for NCI’s National Clinical Trial Network (NCTN) studies since 2019.

Download Full-text

Low adherence to pneumococcal vaccination in lung cancer patients in a tertiary care university hospital in Southern Germany

10.21203/rs.3.rs-906318/v1 ◽

2021 ◽

Author(s):

Arno Mohr ◽

Mia Kloos ◽

Christian Schulz ◽

Michael Pfeifer ◽

Bernd Salzberger ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Medical Records ◽

Hepatitis A ◽

Tertiary Care ◽

Pneumococcal Vaccination ◽

University Hospital ◽

Lung Cancer Patients ◽

Tick Borne Encephalitis ◽

The University

Abstract IntroductionThe aim of this study was to investigate the adherence to vaccinations, especially pneumococcal vaccinations, in lung cancer patients.MethodsThe study was performed at the University Hospital Regensburg, Germany. All patients with a regular appointment scheduled between December 1, 2020, and April 29, 2021, and who provided informed consent were included. Available medical records, vaccination certificates and a questionnaire were analyzed.Results136 lung cancer patients (NSCLC n = 113, 83.1%, SCLC n = 23, 16.9%) were included. A correct pneumococcal vaccination according to national recommendations was performed in 9.4% (12/127) of patients.A correct vaccination was performed for tetanus in 50.4% (6/131), diphtheria in 34.4% (44/128), poliomyelitis in 25.8% (33/128), tick-borne encephalitis in 40.7% (24/59), hepatitis A in 45.5% (7/11), hepatitis B in 38.5% (5/13), shingles in 3.0% (3/101), measles in 50.0% (3/6), pertussis in 47.7% (62/130), influenza in 54.4% (74/136) and meningococcal meningitis in 0% (0/2).ConclusionAdherence to pneumococcal vaccinations, as well as other vaccinations, is rather low in lung cancer patients.

Download Full-text